Treatment Hands
FDA Approved Treatments
There are currently 7 products approved by the FDA for preventing and treating HAE attacks. (Therapies are listed in alphabetical order):

  • BERINERT® - is an FDA-approved C1-inhibitor concentrate for treating acute HAE attacks in adults and pediatric patients. Berinert is delivered intravenously and is approved for on-demand treatment through self-administration. The medicine is usually administered when a patient feels an attack coming on. For more information go to: www.berinert.com.

  • CINRYZE® - is an FDA-approved C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older). Cinryze is delivered intravenously and is approved for home infusion to prevent HAE attacks. For more information go to: www.cinryze.com.

  • FIRAZYR® - is an FDA-approved B2 bradykinin receptor antagonist for treating acute HAE attacks in patients 18 years and older. Firazyr is delivered by subcutaneous injection and is approved for self-administration. The medicine is usually administered when a patient feels an attack coming on. For more information go to: www.firazyr.com.

  • HAEGARDA® - is a self-administered, plasma-derived concentrate of C1-esterase inhibitor and the only subcutaneous therapy approved in the United States for routine prophylaxis to prevent HAE attacks in adolescent and adult patients. For more information go to: www.haegarda.com.

  • KALBITOR® - is an FDA-approved kallikrein inhibitor for treating acute HAE attacks in patients 12 years of age and older. Kalbitor is delivered by subcutaneous injection and must be administered by a healthcare professional. For more information go to: www.kalbitor.com.

  • RUCONEST® - is an FDA-approved plasma free recombinant C1-inhibitor concentrate for treating acute HAE attacks in adults and adolescents. Ruconest is delivered intravenously and is approved for self-administration. The medicine is usually administered when a patient feels an attack coming on. For more information go to: www.ruconest.com.

  • TAKHZYRO® - is an FDA-approved plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older. TAKHZYRO is administered through subcutaneous injectable medicine once every 2 weeks to help prevent attacks of HAE in people 12 years of age and older. For more information go to: www.takhzyro.com.